One of our guest we bring you in this episode is a self-described industry dinosaur. The reason he can make a claim like that, of course, is his longevity.

But also, perhaps without knowing it, he can make that claim because of the long-term impact he has had on health care. In fact, if you look back over the past 30 years of pharmaceuticals, you can see his fingerprints on so many of the advancements that we take for granted today. This dinosaur is Steve Aselage. He is a member of the board of directors of Travere Therapeutics where he previously was CEO.

He is joined on this episode by his daughter, Beth Aselage, Associate Director of Advocacy Relations for Gossamer Bio. Beth speaks with a wisdom that combines analytical insights with an abiding desire to advocate on behalf of patients. She has a unique ability to harvest what is most important to patients and to fuse them into an ongoing development for pharmaceutical companies.

Of course the insight that they offer is second-to-none. However, we wanted to bring you the two of them together for an even bigger reason. We wanted you to know about the depth of the legacy that a passion for serving patients can have. When that passion is more than just a saying, patient-first mentalities have the power to change our industry for years to come.

Please subscribe and keep listening to Rare Voices!


More About Steve and Beth


Steve Aselage Linkedin
Beth Aselage Linkedin
Beth Email


Gossamer Bio
Travere Therapeutics

Steve Bio:

Steve Aselage has been a member of the board of directors of Travere Therapeutics, Inc., since 2012. Mr. Aselage is Chairman of the Board of Directors for Acer Therapeutics and also serves on the Board of BioCryst, both of which focus in the rare disease area. During his tenure as CEO of Travere from 2014 to January 2019, Mr. Aselage drew upon more than 30 years of biopharmaceutical experience to lead the transformation of the company. Following his appointment, Mr. Aselage solidified the company’s leadership, led an operational review of pipeline and commercial assets, and built a growth strategy around investigational and commercial therapies to bring long-term value to patients and shareholders. Prior to his appointment, Mr. Aselage was executive vice president and chief business officer of BioMarin Pharmaceutical Inc. During his seven years with BioMarin, Mr. Aselage built the commercial and medical affairs functions that launched three commercial products and developed commercial businesses in more than 45 countries. Mr. Aselage has also held leadership roles with Cell Therapeutics, Sangstat Medical Corporation, Advanced Tissue Sciences and Genentech. Mr. Aselage worked briefly for Genzyme, as well, assisting in the transition following its acquisition of Sangstat, and earlier in his career, held a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi) and Bristol Laboratories. Mr. Aselage received his B.S. in biology from the University of Notre Dame, and currently serves on the advisory council for the Department of Science at the University of Notre Dame.

Beth Bio:

Associate Director, Advocacy Relations at Gossamer Bio

Since recording, Ms. Aselage has accepted an Associate Director of Advocacy Relations position with Gossamer Bio, a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in the disease areas of immunology, inflammation and oncology based in San Diego, CA. Ms. Aselage has over seven years of experience working in the life sciences industry, specializing specifically in rare disease patient advocacy, advocacy engagement, and strategic alliances. Formerly, a Senior Patient Advocacy & Alliance Management Specialist at Retrophin, Ms. Aselage was responsible for identifying and incorporating new preclinical stage research programs into the company’s corporate pipeline by collaborating with patient advocacy organizations, and top research institutions. An emerging leader in patient advocacy partnerships in industry, in 2017 Ms. Aselage led efforts in execution of the first of kind collaborative research and development agreement (CRADA) between partners in advocacy, industry, and researchers at the National Institutes of Health (NIH). Ms. Aselage remains committed to supporting and advocating on behalf of the rare disease community, and currently sits on the Board of Directors for the Little Miss Hannah Foundation.

Ms. Aselage received her Bachelor of Arts with Honors from Michigan State University in 2013, and more recently, her Master’s in Business Administration (MBA) from California State University Monterey Bay.

Subscribe here:

iTunes   •   Soundcloud   •   Stitcher    •    Youtube

Music Credits:

Westpoint Instrumental by  Sun Shapes